SCHEMBL23328400

SCHEMBL23328400

O=S(=O)(O)CCNC(=S)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.67
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
LMNA P02545 4/20 0.62
HTT P42858 3/20 0.62
MAPT P10636 4/20 0.55
GAA P10253 2/20 0.55
ALDH1A1 P00352 2/20 0.55
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA12 O43570 3/20 0.47
CA9 Q16790 3/20 0.47
CA4 P22748 1/20 0.47
CA7 P43166 1/20 0.47
EPHX2 P34913 1/20 0.46
ALOX12 P18054 1/20 0.45
KIF11 P52732 1/20 0.44
CXCR4 P61073 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23328393 0.93 SMN1; SMN2 (0.68) CDK1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL23328405 0.92 SMN1; SMN2 (0.67) CDK1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL23328363 0.87 CDK1 (0.63) CDK1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL23328404 0.84 MEN1 (0.67) MEN1KMT2AMAPTCA1CA2
SCHEMBL23328872 0.81 SMN1; SMN2 (0.63) CDK1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL25840779 0.81 SMN1; SMN2 (0.54) MEN1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL14386216 0.80 CDK1 (1.00) CDK1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL23328667 0.80 SMN1; SMN2 (0.66) CDK1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL23328398 0.79 MEN1 (0.63) MEN1KMT2ASMN1; SMN2LMNAHTT
SCHEMBL27922871 0.78 CDK1 (0.68) CDK1MEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701333-B2 Antibacterial compounds ARF1, ARL1, TLR1 CDK1 1597/4885MEN1 1300/4885KMT2A 2533/4885
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS ARF1, ARL1, TLR1 CDK1 1597/4885MEN1 1300/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.